Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months ...

Bevacizumab biosimilar LY01008 demonstrated comparative safety, efficacy, immunogenicity, and pharmacokinetic profiles to the reference product Avastin when combined with paclitaxel and carboplatin in ...

Cardiff Oncology (NASDAQ:CRDF) outlined a management transition and provided an updated clinical data readout for onvansertib during a company conference call focused on its ongoing Phase II CRDF-004 ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...

Corey J. Langer, MD, FACP: Personally, I believe there’s still a role for bevacizumab in select patients despite the astounding survival advantages seen with KEYNOTE-189. There are patients who aren’t ...

Please provide your email address to receive an email when new articles are posted on . When added to chemotherapy, extending the duration of bevacizumab treatment from 15 to 30 months failed to ...

Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer Patients with MCRC were randomly ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with a step therapy protocol of bevacizumab injections for neovascular age-related macular ...

A new formulation of bevacizumab for neovascular age-related macular degeneration (nAMD) is headed for evaluation by the US Food and Drug Administration (FDA) amid controversy about a phase 3 trial.

Bevacizumab (Avastin, Roche/Genentech) significantly extended survival by nearly 4 months in patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard surgery ...